Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
Fulgent Genetics預計2024年核心營業收入約爲2.8億美元，非GAAP虧損預計從每股約1.05美元降至每股約0.30美元，而市場預期爲2.8018億美元和每股0.92美元。
Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
Fulgent Genetics預計2024年核心營業收入約爲2.8億美元，非GAAP虧損預計從每股約1.05美元降至每股約0.30美元，而市場預期爲2.8018億美元和每股0.92美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。